Philippe Merle
Impact in
- Hepatology top 0.02%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
Papers in
- Hepatology 113
- Hepatocellular Carcinoma Treatment and Prognosis 96
- Hepatitis C virus research 16
- Liver physiology and pathology 10
- Oncology 42
- Colorectal Cancer Treatments and Studies 19
- Pancreatic and Hepatic Oncology Research 10
- Co-authors
- Masatoshi Kudo (24 shared papers)Ann‐Lii Cheng (22 shared papers)Richard S. Finn (13 shared papers)Jack R. Wands (7 shared papers)Christian Trépo (11 shared papers)Miran Kim (5 shared papers)Lorenza Rimassa (13 shared papers)Peter Robert Galle (10 shared papers)
- Journals
- Annals of Oncology (26 papers)Journal of Hepatology (24 papers)Liver Cancer (12 papers)Liver International (6 papers)The Lancet Oncology (5 papers)
- Partner nations
- FranceUnited StatesJapan
In The Last Decade
Philippe Merle
190 papers receiving 23.1k citations
Philippe Merle's Hit Papers
Peers
Comparison fields: 5 of 138
- Hepatology 12.9k
- Oncology 5.7k
- Cancer Research 3.0k
- Pathology and Forensic Medicine 2.8k
- Epidemiology 4.2k
Countries citing papers authored by Philippe Merle
This map shows the geographic impact of Philippe Merle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Merle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Merle more than expected).
Fields of papers citing papers by Philippe Merle
This network shows the impact of papers produced by Philippe Merle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Merle. The network helps show where Philippe Merle may publish in the future.
Co-authors
The 25 scholars most cited alongside Philippe Merle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 198 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Hit paper breakdown → | 2020 | 5498 |
| 2 | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2016 | 3032 |
| 3 | Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma Hit paper breakdown → | 2018 | 1893 |
| 4 | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial Hit paper breakdown → | 2019 | 1485 |
| 5 | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2019 | 1386 |
| 6 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Hit paper breakdown → | 2021 | 1228 |
| 7 | Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial Hit paper breakdown → | 2017 | 653 |
| 8 | CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) Hit paper breakdown → | 2019 | 560 |
| 9 | Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2022 | 436 |
| 10 | Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 313 |
| 11 | 2002 | 301 | |
| 12 | Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial Hit paper breakdown → | 2018 | 294 |
| 13 | Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial Hit paper breakdown → | 2021 | 288 |
| 14 | 2013 | 232 | |
| 15 | 2004 | 220 | |
| 16 | 2019 | 211 | |
| 17 | 2008 | 187 | |
| 18 | 2019 | 186 | |
| 19 | 2005 | 186 | |
| 20 | 2000 | 184 |
About Philippe Merle
Philippe Merle is a scholar working on Hepatology, Oncology, Epidemiology, Cancer Research and Pathology and Forensic Medicine, having authored 198 papers that have together received 23.4k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (96 papers), Hepatitis B Virus Studies (24 papers), Colorectal Cancer Treatments and Studies (19 papers), Liver Disease Diagnosis and Treatment (19 papers), Hepatitis C virus research (16 papers), Cancer Mechanisms and Therapy (10 papers), Pancreatic and Hepatic Oncology Research (10 papers) and Liver physiology and pathology (10 papers). The work is most often cited by research in Hepatology (12.9k citations), Oncology (5.7k citations), Cancer Research (3.0k citations), Pathology and Forensic Medicine (2.8k citations) and Epidemiology (4.2k citations). Philippe Merle has collaborated with scholars based in France, United States and Japan. Frequent co-authors include Masatoshi Kudo, Ann‐Lii Cheng, Richard S. Finn, Jack R. Wands, Christian Trépo, Miran Kim, Lorenza Rimassa, Peter Robert Galle, Valeriy Vladimirovich Breder and Tiziana Pressiani. Their work appears in journals such as Annals of Oncology, Journal of Hepatology, Liver Cancer, Liver International and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.